Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Loss for the period	$ (15,760)	$ (12,503)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	28	22
Stock-based compensation	121	239
Issuance of restricted shares as compensation towards directors		178
Linkage difference on principal of loans from stockholders		1
Revaluation expenses incurred from settlement of financial liabilities		1,505
Revaluation expenses related to derivative financial liabilities		2
Change in fair value of derivative liability	3,269
Amortization of debt discount and interest expense related to promissory notes	5	330
Amortization of original issue discount related to promissory note	31
Loss on warrant repurchase	99
Changes in assets and liabilities:
Other current assets	(86)	80
Accounts payable	717	1,129
Other current liabilities	272	26
Net cash used in operating activities	(11,304)	(8,991)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(76)	(104)
Net cash used in investing activities	(76)	(104)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from underwritten U.S. public offerings (Note 3A)	10,715
Net proceeds from promissory note	3,000
Series A warrant repurchase	(166)
Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction		360
Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction		4,000
Issuance of notes and warrants through private placement transaction		100
Net proceeds from private placement transaction		500
Net cash provided by financing activities	13,549	4,960
Effect of exchange rate changes on cash and cash equivalents, and restricted cash	73	(11)
Change in cash and cash equivalents, and restricted cash	2,242	(4,146)
Cash and cash equivalents, and restricted cash at beginning of the period	5,627	4,502
Cash and cash equivalents, and restricted cash, end of period	7,869	356
(a) Net cash received during the quarter for:
Interest	120	37
(b) Non-cash activities:
Issuance of shares and warrants as settlement of financial liabilities		238
Recognition of right for usage asset against a lease liability		$ 79

Glucotrack, Inc. 10-Q